Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Journal of Experimental Hematology ; (6): 971-974, 2012.
Article Dans Chinois | WPRIM | ID: wpr-278454

Résumé

The objective of this study was to explore the incidence and therapeutic efficacy of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical data of 140 patients undergoing allo-HSCT in our department of hematology from 2010-01 to 2012-01 were retrospectively analyzed. The results showed that the incidence of CMV infection was 4.3% (48/140), the time for the first detection of positive CMV-DNA was at day 45 (33 to 68) after allo-HSCT, and the CMV quantitative range was 1.25×10(3) - 5.5×10(6). There were 2 cases of CMV-related interstitial pneumonia and 5 cases of hemorrhagic bladder inflammation. A total of 65 patients suffered from graft versus host disease (GVHD), in which 32 cases (49.2%) were accompanied with CMV infection, CMV-DNA negative in patients treated with ganciclovir, foscarnet sodium anti-CMV was at day 45 (33 to 68) with the effective rate of 100%. 12 patients with CMV infection were accompanied with transient neutropenia and thrombocytopenia. It is concluded that after allo-HSCT the CMV infection occurs frequently. The patients with GVHD have a higher incidence of CMV infection. Ganciclovir and foscarnet sodium are reliable to be used for treatment of CMV infection with fewer adverse reactions.


Sujets)
Adolescent , Adulte , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Infections à cytomégalovirus , Traitement médicamenteux , Foscarnet , Utilisations thérapeutiques , Ganciclovir , Utilisations thérapeutiques , Maladie du greffon contre l'hôte , Transplantation de cellules souches hématopoïétiques , Études rétrospectives , Facteurs de risque , Transplantation homologue
2.
Journal of Experimental Hematology ; (6): 855-857, 2004.
Article Dans Chinois | WPRIM | ID: wpr-347845

Résumé

The study was aimed to explore clinical result of cyclosporin A (CsA) and androgens for treatment of myelodysplastic syndrome (MDS) with refractory anemia. Four cases of MDS-RA were treated with CsA and androgens, while the changes of blood counts, bone marrow and chromosome were observed. The results showed that substantial hematological response was observed in all four patients, that their anemia improved and all transfusion-dependent patients achieved transfusion independence. In conclusion, CsA and Adr therapy was well tolerated. CsA and Adr therapy offer an alternative treatment of MDS with RA. The mechanisms of the benifical effect from this therapy remain the subject of an ongoing study.


Sujets)
Adolescent , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Androgènes , Utilisations thérapeutiques , Hémogramme , Ciclosporine , Utilisations thérapeutiques , Association de médicaments , Hémoglobines , Immunosuppresseurs , Utilisations thérapeutiques , Syndromes myélodysplasiques , Sang , Traitement médicamenteux , Résultat thérapeutique
SÉLECTION CITATIONS
Détails de la recherche